Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb9c6b40161bafe7bd55f0b4defcea04 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-555 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 |
filingDate |
2019-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d215db0e86eec95bae03ea28458ec8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_563077d61e14e1222581f66d6d8fce28 |
publicationDate |
2020-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CA-3115818-A1 |
titleOfInvention |
Degraders of wild-type and mutant forms of lrrk2 |
abstract |
Disclosed are bifunctional compounds (degraders) that target LRKK2 for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the degraders to treat neurodegenerative diseases and disorders such as Parkinson's disease and brain cancer (e.g., gliomas and glioblastomas). |
priorityDate |
2018-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |